Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

452 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
Devos T, Geukens T, Schauwvlieghe A, Ariën KK, Barbezange C, Cleeren M, Compernolle V, Dauby N, Desmecht D, Grimaldi D, Lambrecht BN, Luyten A, Maes P, Moutschen M, Romano M, Seyler L, Nevessignsky MT, Vandenberghe K, van Griensven J, Verbeke G, Vlieghe E, Yombi JC, Liesenborghs L, Verhamme P, Meyfroidt G. Devos T, et al. Among authors: verhamme p. Trials. 2020 Dec 14;21(1):1024. doi: 10.1186/s13063-020-04947-2. Trials. 2020. PMID: 33317581 Free PMC article. No abstract available.
Coagulation: At the heart of infective endocarditis.
Liesenborghs L, Meyers S, Vanassche T, Verhamme P. Liesenborghs L, et al. Among authors: verhamme p. J Thromb Haemost. 2020 May;18(5):995-1008. doi: 10.1111/jth.14736. Epub 2020 Feb 3. J Thromb Haemost. 2020. PMID: 31925863 Free article. Review.
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
Devos T, Geukens T, Schauwvlieghe A, Ariën KK, Barbezange C, Cleeren M, Compernolle V, Dauby N, Desmecht D, Grimaldi D, Lambrecht BN, Luyten A, Maes P, Moutschen M, Romano M, Seyler L, Nevessignsky MT, Vandenberghe K, van Griensven J, Verbeke G, Vlieghe E, Yombi JC, Liesenborghs L, Verhamme P, Meyfroidt G. Devos T, et al. Among authors: verhamme p. Trials. 2020 Nov 27;21(1):981. doi: 10.1186/s13063-020-04876-0. Trials. 2020. PMID: 33246499 Free PMC article. Clinical Trial.
A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study.
Vanassche T, Engelen MM, Van Thillo Q, Wauters J, Gunst J, Wouters C, Vandenbriele C, Rex S, Liesenborghs L, Wilmer A, Meersseman P, Van den Berghe G, Dauwe D, Verbeke G, Thomeer M, Fivez T, Mesotten D, Ruttens D, Heytens L, Dapper I, Tuyls S, De Tavernier B, Verhamme P; DAWn consortium members. Vanassche T, et al. Among authors: verhamme p. Trials. 2020 Dec 9;21(1):1005. doi: 10.1186/s13063-020-04878-y. Trials. 2020. PMID: 33298149 Free PMC article. Clinical Trial.
Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies.
Betrains A, Godinas L, Woei-A-Jin FJSH, Rosseels W, Van Herck Y, Lorent N, Dierickx D, Compernolle V, Meyfroidt G, Vanderbeke L, Vergote V, Lagrou K, Verhamme P, Wauters J, Vermeersch P, Devos T, Maes P, Vanderschueren S. Betrains A, et al. Among authors: verhamme p. Br J Haematol. 2021 Mar;192(6):1100-1105. doi: 10.1111/bjh.17266. Epub 2020 Dec 13. Br J Haematol. 2021. PMID: 33314018 Free article. No abstract available.
Correction to: A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study.
Vanassche T, Engelen MM, Van Thillo Q, Wauters J, Gunst J, Wouters C, Vandenbriele C, Rex S, Liesenborghs L, Wilmer A, Meersseman P, Van den Berghe G, Dauwe D, Verbeke G, Thomeer M, Fivez T, Mesotten D, Ruttens D, Heytens L, Dapper I, Tuyls S, De Tavernier B, Verhamme P; DAWn consortium members. Vanassche T, et al. Among authors: verhamme p. Trials. 2020 Dec 29;21(1):1033. doi: 10.1186/s13063-020-04991-y. Trials. 2020. PMID: 33375932 Free PMC article. No abstract available.
Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.
Gyselinck I, Liesenborghs L, Landeloos E, Belmans A, Verbeke G, Verhamme P, Vos R, Janssens W; DAWn-Azithro consortium. Gyselinck I, et al. Among authors: verhamme p. Trials. 2021 Feb 9;22(1):126. doi: 10.1186/s13063-021-05033-x. Trials. 2021. PMID: 33563325 Free PMC article.
Correction to: Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.
Gyselinck I, Liesenborghs L, Landeloos E, Belmans A, Verbeke G, Verhamme P, Vos R, Janssens W; DAWn-Azithro consortium. Gyselinck I, et al. Among authors: verhamme p. Trials. 2021 Mar 5;22(1):187. doi: 10.1186/s13063-021-05153-4. Trials. 2021. PMID: 33673831 Free PMC article. No abstract available.
452 results